Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.37 |
| ▸ | MC4R | P32245 | 6/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.30 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486330 | 0.94 | BMPR1B (0.38) | KITMC4RRETBMPR1BBMPR1A | |
| SCHEMBL19486752 | 0.94 | BMPR1B (0.38) | KITMC4RRETBMPR1BBMPR1A | |
| SCHEMBL19486483 | 0.92 | PARP1 (0.39) | KITMC4RRETBMPR1BBMPR1A | |
| SCHEMBL19486842 | 0.92 | PARP1 (0.39) | KITMC4RRETBMPR1BBMPR1A | |
| SCHEMBL19486477 | 0.91 | KCNH2 (0.38) | KITMC4RBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL19486352 | 0.85 | KIT (0.39) | KITTGFBR1ACVR1KCNH2HRH3 | |
| SCHEMBL19459081 | 0.85 | RET (0.41) | KITMC4RRETTGFBR1ACVR1 | |
| SCHEMBL25765606 | 0.84 | KIT (0.37) | KITMC4RRETBMPR1BBMPR1A | |
| SCHEMBL19459170 | 0.83 | MC4R (0.40) | KITMC4RRET | |
| SCHEMBL19486377 | 0.83 | KIT (0.36) | KITRETHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KIT 27/4885MC4R 3611/4885RET 56/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KIT 189/4885MC4R 3673/4885RET 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.